[Fabry disease: Pathogenesis, pathophysiology, and therapy].
Utsumi
Kouichi
K
Second Department of Internal Medicine, Nippon Medical School.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D041321:Chromosomes, Human, X; D003937:Diagnosis, Differential; D000795:Fabry Disease / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D005808:Genes, Recessive; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use; D009154:Mutation; D010138:Pacemaker, Artificial; D011994:Recombinant Proteins / Q000627:therapeutic use; D014281:Trihexosylceramides / Q000378:metabolism; D016482:Urinalysis / Q000379:methods; D000519:alpha-Galactosidase / Q000235:genetics / Q000502:physiology / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D007527:Isoenzymes; D011994:Recombinant Proteins; D014281:Trihexosylceramides; C018549:globotriaosylceramide; D000519:alpha-Galactosidase; C459420:agalsidase beta